NASDAQ:ADAP

Adaptimmune Therapeutics SEC Filings & 10K Form

$5.25
-0.15 (-2.78 %)
(As of 09/16/2021 02:29 PM ET)
Add
Compare
Today's Range
$5.08
$5.70
50-Day Range
$3.44
$6.37
52-Week Range
$3.37
$10.93
Volume107,313 shs
Average Volume1.29 million shs
Market Capitalization$819.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17

Adaptimmune Therapeutics (NASDAQ:ADAP) SEC Filings

DateFilerForm TypeView
09/13/2021
6:08 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/07/2021
6:08 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/01/2021
8:00 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2021
7:01 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2021
7:01 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2021
8:01 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2021
3:31 PM
Adaptimmune Therapeutics (Issuer)
Alleva Lawrence M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2021
4:08 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2021
7:39 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2021
6:38 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/08/2021
7:00 AM
Adaptimmune Therapeutics (Filer)
Form DEF 14A
03/29/2021
7:00 AM
Adaptimmune Therapeutics (Filer)
Form PRE 14A
03/03/2021
8:01 PM
Adaptimmune Therapeutics (Issuer)
TAYTON-MARTIN HELEN KATRINA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2021
3:18 PM
Adaptimmune Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/25/2021
6:37 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/16/2021
10:42 AM
Adaptimmune Therapeutics (Subject)
Capital World Investors (Filed by)
Form SC 13G
02/16/2021
9:03 AM
Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
Form SC 13G/A
01/28/2021
5:36 AM
Adaptimmune Therapeutics (Subject)
BAILLIE GIFFORD & CO (Filed by)
Form SC 13G
01/19/2021
8:01 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/19/2021
8:01 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/19/2021
8:00 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2021
8:01 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2021
8:01 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2021
8:00 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2021
8:00 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
8:03 PM
Adaptimmune Therapeutics (Issuer)
Wood Gavin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
8:02 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
8:02 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
8:01 PM
Adaptimmune Therapeutics (Issuer)
TAYTON-MARTIN HELEN KATRINA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
8:00 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2021
8:00 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
8:02 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
8:01 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
8:00 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
8:00 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2020
8:00 PM
Adaptimmune Therapeutics (Issuer)
Wood Gavin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2020
4:01 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/15/2020
8:00 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2020
6:36 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/19/2020
8:09 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/09/2020
4:11 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2020
6:40 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2020
8:28 AM
Adaptimmune Therapeutics (Filer)
Form CT ORDER
10/15/2020
3:47 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/02/2020
8:00 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2020
9:44 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2020
10:17 AM
Adaptimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/06/2020
6:37 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/04/2020
8:02 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/04/2020
8:02 PM
Adaptimmune Therapeutics (Issuer)
TAYTON-MARTIN HELEN KATRINA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/04/2020
8:01 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2020
4:13 PM
Adaptimmune Therapeutics (Issuer)
Behbahani Ali (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2020
4:10 PM
Adaptimmune Therapeutics (Issuer)
Zaks Tal Zvi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2020
4:09 PM
Adaptimmune Therapeutics (Issuer)
Alleva Lawrence M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2020
4:09 PM
Adaptimmune Therapeutics (Issuer)
Furey John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2020
4:08 PM
Adaptimmune Therapeutics (Issuer)
Noble James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2020
4:07 PM
Adaptimmune Therapeutics (Issuer)
Sigal Charles Elliott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2020
4:07 PM
Adaptimmune Therapeutics (Issuer)
MOTT DAVID M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2020
4:06 PM
Adaptimmune Therapeutics (Issuer)
Duncan Barbara Gayle (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2020
8:01 PM
Adaptimmune Therapeutics (Issuer)
Wood Gavin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2020
8:00 PM
Adaptimmune Therapeutics (Issuer)
Alleva Lawrence M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2020
8:30 PM
Adaptimmune Therapeutics (Issuer)
Noble James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2020
4:05 PM
Adaptimmune Therapeutics (Filer)
Form 424B5
06/02/2020
3:49 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/01/2020
5:06 AM
Adaptimmune Therapeutics (Filer)
Form 424B5
05/29/2020
6:42 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2020
6:07 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/28/2020
3:37 PM
Adaptimmune Therapeutics (Filer)
Form 10-Q/A
05/14/2020
10:02 AM
Adaptimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2020
6:37 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2020
7:06 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/28/2020
7:26 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/20/2020
7:00 AM
Adaptimmune Therapeutics (Filer)
Form DEF 14A
04/08/2020
7:06 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/08/2020
7:00 AM
Adaptimmune Therapeutics (Filer)
Form PRE 14A
04/01/2020
6:06 PM
Adaptimmune Therapeutics (Issuer)
Noble James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2020
6:06 PM
Adaptimmune Therapeutics (Issuer)
Wood Gavin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2020
6:05 PM
Adaptimmune Therapeutics (Issuer)
Wood Gavin (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
02/27/2020
10:50 AM
Adaptimmune Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/27/2020
6:39 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/18/2020
7:07 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/07/2020
3:20 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/28/2020
3:52 PM
Adaptimmune Therapeutics (Issuer)
Florence Anthony A. Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/28/2020
3:52 PM
Adaptimmune Therapeutics (Issuer)
Behbahani Ali (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/28/2020
3:51 PM
Adaptimmune Therapeutics (Issuer)
BASKETT FOREST (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2020
4:31 PM
Adaptimmune Therapeutics (Filer)
Form 424B5
01/22/2020
4:30 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/21/2020
4:21 PM
Adaptimmune Therapeutics (Filer)
Form 424B5
01/17/2020
8:48 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2020
8:35 PM
Adaptimmune Therapeutics (Issuer)
TAYTON-MARTIN HELEN KATRINA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2020
8:33 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2020
8:31 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2020
8:30 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2020
7:03 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2020
7:03 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2020
7:02 PM
Adaptimmune Therapeutics (Issuer)
TAYTON-MARTIN HELEN KATRINA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2020
7:02 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2020
7:01 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2020
7:01 PM
Adaptimmune Therapeutics (Issuer)
Noble James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2020
5:17 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.